1/2/2020 7:35:45 AM
MediWound Inks Deal Granting Balance Medical Exclusive Rights To Market NexoBrid In Australia, New Zealand And Singapore
12/3/2019 8:41:44 AM
MediWound Initiates U.S. Phase 2 Adaptive Design Study Of EscharEx For Treatment Of Venous Leg Ulcers
10/2/2019 7:36:47 AM
Vericel And MediWound Begin U.S. NexoBrid Expanded Access Treatment Protocol
1/22/2019 6:32:41 AM
MediWound Announces Positive Top-Line Results From Pivotal Phase 3 Study (DETECT) In NexoBrid
11/13/2018 7:25:14 AM
MediWound Q3 Net Loss $2.9 Mln Or $0.11/Shr Vs Net Loss $11.0 Mln Or $0.49/Shr Last Year
9/5/2018 7:03:01 AM
MediWound Receives Marketing Authorization From Russia's Ministry Of Health
8/7/2018 7:19:58 AM
MediWound Q2 Net Loss $4.2 Mln Or $0.15 Per Share
6/19/2018 7:06:12 AM
MediWound Expands NexoBrid Phase 3 Children Innovation Debridement Study To The U.S.
6/11/2018 7:04:09 AM
MediWound Completes Enrollment In NexoBrid U.S. Phase 3 DETECT Study
5/29/2018 8:06:28 AM
MediWound: FDA Clears Development Pathway For NexoBrid® For Sulfur Mustard Injuries
5/10/2018 7:11:49 AM
MediWound Q1 Net Loss Flat At $4.6 Mln
3/19/2018 7:05:23 AM
MediWound FY Total Revenues $2.5 Mln, Up 60%